Form 4: Gilead Sciences CEO Sells Shares Under Pre-Arranged Trading Plan

Gilead Sciences' Chairman and CEO, Daniel Patrick O'Day, sold 10,000 shares of common stock on July 28, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Daniel Patrick O'Day, Chairman & CEO of Gilead Sciences, Inc. (GILD), executed sales of common stock.
• The transactions occurred on July 28, 2025.
• A total of 10,000 shares of common stock were sold in two separate transactions.
• 1,655 shares were sold at an average price of $113.1678, with prices ranging from $112.71 to $113.59.
• 8,345 shares were sold at an average price of $114.0895, with prices ranging from $113.71 to $114.56.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
• Following these transactions, Daniel Patrick O'Day beneficially owns 605,725 shares of Gilead Sciences common stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling by a top executive, although the impact is mitigated by the fact that the sale was pre-planned under a Rule 10b5-1 plan, suggesting it was not driven by new adverse information.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was not a reaction to recent negative company developments but a scheduled transaction.

Negatives

• The sale of 10,000 shares by the Chairman & CEO represents a reduction in direct insider ownership.

Risks

• Insider selling, even when pre-planned, can sometimes be perceived by the market as a lack of strong conviction in the company's near-term stock price appreciation by a key executive.

Future Outlook

This Form 4 filing pertains to an insider stock transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitive dynamics within the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: Insider selling can influence investor sentiment and perceptions of management's confidence in the company's future prospects.

Key Dates

Recommendation

The sale of shares by the Chairman & CEO, while executed under a pre-arranged Rule 10b5-1 plan, represents a reduction in insider ownership. While not indicative of immediate negative news, it does not provide a strong positive signal for future stock appreciation, suggesting a 'hold' position for investors who may view this as a neutral to slightly negative event.

Keywords

Gilead Sciences, GILD, Form 4, Insider Trading, Stock Sale, Daniel O'Day, CEO, 10b5-1 Plan, Executive Compensation